IBDEI1CZ ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24382,2)
 ;;=^269598
 ;;^UTILITY(U,$J,358.3,24383,0)
 ;;=402.11^^145^1525^32
 ;;^UTILITY(U,$J,358.3,24383,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24383,1,4,0)
 ;;=4^402.11
 ;;^UTILITY(U,$J,358.3,24383,1,5,0)
 ;;=5^HTN with CHF
 ;;^UTILITY(U,$J,358.3,24383,2)
 ;;=HTN with CHF^269599
 ;;^UTILITY(U,$J,358.3,24384,0)
 ;;=403.11^^145^1525^37
 ;;^UTILITY(U,$J,358.3,24384,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24384,1,4,0)
 ;;=4^403.11
 ;;^UTILITY(U,$J,358.3,24384,1,5,0)
 ;;=5^HTN with Renal Failure
 ;;^UTILITY(U,$J,358.3,24384,2)
 ;;=^269608
 ;;^UTILITY(U,$J,358.3,24385,0)
 ;;=404.10^^145^1525^35
 ;;^UTILITY(U,$J,358.3,24385,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24385,1,4,0)
 ;;=4^404.10
 ;;^UTILITY(U,$J,358.3,24385,1,5,0)
 ;;=5^HTN with Heart & Renal Involvement
 ;;^UTILITY(U,$J,358.3,24385,2)
 ;;=^269618
 ;;^UTILITY(U,$J,358.3,24386,0)
 ;;=404.11^^145^1525^33
 ;;^UTILITY(U,$J,358.3,24386,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24386,1,4,0)
 ;;=4^404.11
 ;;^UTILITY(U,$J,358.3,24386,1,5,0)
 ;;=5^HTN with CHF & Renal Involvement
 ;;^UTILITY(U,$J,358.3,24386,2)
 ;;=^269619
 ;;^UTILITY(U,$J,358.3,24387,0)
 ;;=404.12^^145^1525^36
 ;;^UTILITY(U,$J,358.3,24387,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24387,1,4,0)
 ;;=4^404.12
 ;;^UTILITY(U,$J,358.3,24387,1,5,0)
 ;;=5^HTN with Heart Involvement & Renal Failure
 ;;^UTILITY(U,$J,358.3,24387,2)
 ;;=^269620
 ;;^UTILITY(U,$J,358.3,24388,0)
 ;;=404.13^^145^1525^34
 ;;^UTILITY(U,$J,358.3,24388,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24388,1,4,0)
 ;;=4^404.13
 ;;^UTILITY(U,$J,358.3,24388,1,5,0)
 ;;=5^HTN with CHF & Renal failure
 ;;^UTILITY(U,$J,358.3,24388,2)
 ;;=^269621
 ;;^UTILITY(U,$J,358.3,24389,0)
 ;;=401.9^^145^1525^57
 ;;^UTILITY(U,$J,358.3,24389,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24389,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,24389,1,5,0)
 ;;=5^Hypertension, Essential
 ;;^UTILITY(U,$J,358.3,24389,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,24390,0)
 ;;=272.0^^145^1525^55
 ;;^UTILITY(U,$J,358.3,24390,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24390,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,24390,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,24390,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,24391,0)
 ;;=272.1^^145^1525^58
 ;;^UTILITY(U,$J,358.3,24391,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24391,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,24391,1,5,0)
 ;;=5^Hypertriglyceridemia
 ;;^UTILITY(U,$J,358.3,24391,2)
 ;;=Hypertriglyceridemia^101303
 ;;^UTILITY(U,$J,358.3,24392,0)
 ;;=272.2^^145^1525^63
 ;;^UTILITY(U,$J,358.3,24392,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24392,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,24392,1,5,0)
 ;;=5^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,24392,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,24393,0)
 ;;=396.0^^145^1525^11
 ;;^UTILITY(U,$J,358.3,24393,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24393,1,4,0)
 ;;=4^396.0
 ;;^UTILITY(U,$J,358.3,24393,1,5,0)
 ;;=5^Aortic and Mitral Stenosis
 ;;^UTILITY(U,$J,358.3,24393,2)
 ;;=Aortic and Mitral Stenosis^269580
 ;;^UTILITY(U,$J,358.3,24394,0)
 ;;=414.02^^145^1525^18
 ;;^UTILITY(U,$J,358.3,24394,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24394,1,4,0)
 ;;=4^414.02
 ;;^UTILITY(U,$J,358.3,24394,1,5,0)
 ;;=5^CAD, Occlusion of Venous Graft
 ;;^UTILITY(U,$J,358.3,24394,2)
 ;;=CAD, Occlusion of Venous Graft^303282
 ;;^UTILITY(U,$J,358.3,24395,0)
 ;;=459.10^^145^1525^73
 ;;^UTILITY(U,$J,358.3,24395,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24395,1,4,0)
 ;;=4^459.10
 ;;^UTILITY(U,$J,358.3,24395,1,5,0)
 ;;=5^Post Phlebotic Syndrome
